2002
DOI: 10.1001/archderm.138.8.1054
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Cutaneous T-Cell Lymphoma With Combined Immunomodulatory Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
87
2
2

Year Published

2003
2003
2014
2014

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 112 publications
(92 citation statements)
references
References 33 publications
1
87
2
2
Order By: Relevance
“…For example, in a cohort of 51 patients (42 of which had advancedstage disease) treated with single-agent, low-dose, interferon-alpha, responses were observed in 34 (67%), 21 (41%) of which were complete and maintained long-term in nine patients [288]. Similarly, in a cohort of 47 patients with stage III/IV disease, 89% of which had peripheral blood involvement, a response rate exceeding 80% was observed in those treated with a combination of ECP and interferonalpha [302]. Interferon-alpha is associated with myelosuppression, transaminitis and dose-limiting flu-like side effects, particularly at higher doses.…”
Section: Interferon-alphamentioning
confidence: 96%
See 2 more Smart Citations
“…For example, in a cohort of 51 patients (42 of which had advancedstage disease) treated with single-agent, low-dose, interferon-alpha, responses were observed in 34 (67%), 21 (41%) of which were complete and maintained long-term in nine patients [288]. Similarly, in a cohort of 47 patients with stage III/IV disease, 89% of which had peripheral blood involvement, a response rate exceeding 80% was observed in those treated with a combination of ECP and interferonalpha [302]. Interferon-alpha is associated with myelosuppression, transaminitis and dose-limiting flu-like side effects, particularly at higher doses.…”
Section: Interferon-alphamentioning
confidence: 96%
“…Responses, which may be achieved within a few months, are observed in patients with tumor-stage MF and SS. Furthermore, interferon-alpha may be successfully combined with a number of other therapeutic modalities, including PUVA, bexarotene, chemotherapy and ECP, which are frequently utilized in the management of these patients [289][290][291][292][293][294][295][296][297][298][299][300][301][302]. For example, in a cohort of 51 patients (42 of which had advancedstage disease) treated with single-agent, low-dose, interferon-alpha, responses were observed in 34 (67%), 21 (41%) of which were complete and maintained long-term in nine patients [288].…”
Section: Interferon-alphamentioning
confidence: 99%
See 1 more Smart Citation
“…76 In the study by Suchin and colleagues, 89% of a consecutive sample of 47 patients had circulating malignant T cells. 126 ECP monotherapy resulted in a 75% ORR and median survival of 66 months. The authors also reported an increase in the ORR and survival duration when ECP was combined with immunostimulatory agents such as IFN-a.…”
Section: Chemotherapy Many Different Chemotherapeuticmentioning
confidence: 96%
“…77 Suchin and colleagues observed a 75% ORR in a retrospective cohort study, and Gottlieb and colleagues reported a CR rate of 25% and a PR rate of 46% from a retrospective chart review of 28 patients with stage III or IV disease. 126,127 In addition, ECP has minimal side-effects. 77,128 Zic and colleagues also reported a CR rate of 25% and PR rate of 25% in a cohort of 20 patients.…”
Section: Retinoids Plus Puva Thomsen and Colleagues Re-mentioning
confidence: 99%